HitGen(SH:688222) Xin Lang Cai Jing·2025-11-05 02:31Core Viewpoint - Chengdu XianDao's stock price has seen a significant increase of 92.99% year-to-date, despite a recent decline in the last five trading days [1][2]. Company Overview - Chengdu XianDao Pharmaceutical Development Co., Ltd. was established on February 22, 2012, and went public on April 16, 2020. The company specializes in drug discovery services using its core DEL technology and new drug development project transfers [1]. - The company's main revenue source is drug research and development services, accounting for 99.97% of total revenue, with customized services making up 59.92% [1]. Financial Performance - For the period from January to September 2025, Chengdu XianDao reported a revenue of 370 million yuan, representing a year-on-year growth of 23.98%. The net profit attributable to the parent company was 92.87 million yuan, showing a substantial increase of 208.34% [2]. - The company has distributed a total of 134 million yuan in dividends since its A-share listing, with 43.94 million yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Chengdu XianDao increased by 13.63% to 20,700, while the average circulating shares per person decreased by 11.99% to 19,312 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 9.15 million shares, an increase of 7.20 million shares compared to the previous period [3].